Tangthawornchaikul, S. Vasanawathana, W. Chaiyaratana, P. T. Yenchitsomanus, P. Suriyaphol, P. Avirutnan, K. Chokephaibulkit, F. Matsuda, S. Yoksan, Y. Jacob, G. M. Lathrop, P. Malasit, P. Despres, and C. Julier. 2005. A variant in the CD209 promoter is
associated with severity of dengue disease. Nat. Genet. 37:507-513.
186. Sanchez, V., S. Gimenez, B. Tomlinson, P. K. Chan, G. N. Thomas, R. Forrat, L.
Chambonneau, F. Deauvieau, J. Lang, and B. Guy. 2006. Innate and adaptive cellular
immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24:4914-4926.
187. Sanjay, S., A. M. Wagle, and K. G. Au Eong. 2008. Optic neuropathy associated with dengue fever. Eye 22:722-724.
188. Sanjay, S., A. M. Wagle, and K. G. Au Eong. 2009. Dengue optic neuropathy. Ophthalmology 116:170; author reply 170.
189. Santos, N. Q., A. C. Azoubel, A. A. Lopes, G. Costa, and A. Bacellar. 2004.
Guillain-Barre syndrome in the course of dengue: case report. Arq. Neuropsiquiatr. 62:144- 146.
190. Sariol, C. A., J. L. Munoz-Jordan, K. Abel, L. C. Rosado, P. Pantoja, L. Giavedoni,
I. V. Rodriguez, L. J. White, M. Martinez, T. Arana, and E. N. Kraiselburd. 2007.
Transcriptional activation of interferon-stimulated genes but not of cytokine genes after primary infection of rhesus macaques with dengue virus type 1. Clin. Vaccine Immunol.
14:756-766.
191. Scherer, ,W.F., P. K. Russell, L. Rosen, J. Casals, and R. W. Dickerman. 1978. Experimental infection of chimpanzees with dengue viruses. Am. J. Trop. Med. Hyg. 27:590- 599.
171
192. Schul, W., W. Liu, H. Y. Xu, M. Flamand, and S. G. Vasudevan. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195:665-674. 193. Setiati, T. E., A. T. Mairuhu, P. Koraka, M. Supriatna, M. R. Mac Gillavry, D. P.
Brandjes, A. D. Osterhaus, J. W. van der Meer, E. C. van Gorp, and A. Soemantri.
2007. Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infect. Dis. 7:22.
194. Shabman, R. S., T. E. Morrison, C. Moore, L. White, M. S. Suthar, L. Hueston, N.
Rulli, B. Lidbury, J. P. Ting, S. Mahalingam, and M. T. Heise. 2007. Differential
induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses. J. Virol. 81:237-247.
195. Shabman, R. S., K. M. Rogers, and M. T. Heise. 2008. Ross River virus envelope glycans contribute to type I interferon production in myeloid dendritic cells. J. Virol.
82:12374-12383.
196. Shepard, D. S., J. A. Suaya, S. B. Halstead, M. B. Nathan, D. J. Gubler, R. T.
Mahoney, D. N. Wang, and M. I. Meltzer. 2004. Cost-effectiveness of a pediatric dengue
vaccine. Vaccine 22:1275-1280.
197. Shibuya, N., I. J. Goldstein, E. J. Van Damme, and W. J. Peumans. 1988. Binding properties of a mannose-specific lectin from the snowdrop (Galanthus nivalis) bulb. J. Biol. Chem. 263:728-734.
198. Shresta, S., J. L. Kyle, P. Robert Beatty, and E. Harris. 2004. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology
319:262-273.
199. Shresta, S., J. L. Kyle, H. M. Snider, M. Basavapatna, P. R. Beatty, and E. Harris. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol.
78:2701-2710.
200. Shresta, S., K. L. Sharar, D. M. Prigozhin, P. R. Beatty, and E. Harris. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
201. Shresta, S., K. L. Sharar, D. M. Prigozhin, H. M. Snider, P. R. Beatty, and E.
Harris. 2005. Critical roles for both STAT1-dependent and STAT1-independent pathways in
the control of primary dengue virus infection in mice. J. Immunol. 175:3946-3954. 202. Silva, M. C., A. Guerrero-Plata, F. D. Gilfoy, R. P. Garofalo, and P. W. Mason. 2007. Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J. Virol. 81:13640-13648.
172
203. Silva, R. L., A. M. de Silva, E. Harris, and G. H. MacDonald. 2008. Genetic analysis of Dengue 3 virus subtype III 5' and 3' non-coding regions. Virus Res. 135:320-325.
204. Simasathien, S., S. J. Thomas, V. Watanaveeradej, A. Nisalak, C. Barberousse, B.
L. Innis, W. Sun, J. R. Putnak, K. H. Eckels, Y. Hutagalung, R. V. Gibbons, C. Zhang, R. De La Barrera, R. G. Jarman, W. Chawachalasai, and M. P. Mammen Jr. 2008.
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 78:426-433.
205. Simmons, C. P., T. N. Chau, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Thien, B.
Lien le, N. T. Quy, N. T. Hieu, T. T. Hien, C. McElnea, P. Young, S. Whitehead, N. T. Hung, and J. Farrar. 2007. Maternal antibody and viral factors in the pathogenesis of
dengue virus in infants. J. Infect. Dis. 196:416-424.
206. Simmons, J. J., J. H. St. John, and F. H. K. Reynolds. 1931. Experimental Studies of Dengue. Bureau of Printing, Manila.
207. Simmons, M., K. R. Porter, C. G. Hayes, D. W. Vaughn, and R. Putnak. 2006. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 80:9577- 9585.
208. Smith, G. W., and P. J. Wright. 1985. Synthesis of proteins and glycoproteins in dengue type 2 virus-infected vero and Aedes albopictus cells. J. Gen. Virol. 66 ( Pt 3):559- 571.
209. Soares, C. N., M. Cabral-Castro, C. Oliveira, L. C. Faria, J. M. Peralta, M. R.
Freitas, and M. Puccioni-Sohler. 2008. Oligosymptomatic dengue infection: a potential
cause of Guillain Barre syndrome. Arq. Neuropsiquiatr. 66:234-237.
210. Soares, C. N., L. C. Faria, J. M. Peralta, M. R. de Freitas, and M. Puccioni-Sohler. 2006. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. J. Neurol. Sci. 249:19-24.
211. Soundravally, R., and S. L. Hoti. 2008. Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand. J. Immunol. 67:618- 625.
212. Sriburi, R., P. Keelapang, T. Duangchinda, S. Pruksakorn, N. Maneekarn, P.
Malasit, and N. Sittisombut. 2001. Construction of infectious dengue 2 virus cDNA clones
using high copy number plasmid. J. Virol. Methods 92:71-82.
213. Sun, P., S. Fernandez, M. A. Marovich, D. R. Palmer, C. M. Celluzzi, K. Boonnak,